Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support those living with type 1 and 2 diabetes with the (a) cost of living and (b) the long term impact of those conditions in Hornsey and Friern Barnet constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
To improve the provision of services for the treatment of type 1 and 2 diabetes in the Hornsey and Friern Barnet constituency, the North Central London Integrated Care System has commissioned a long-term conditions service. This supports the identification of individuals with diabetes and at high risk of a worsening condition, personalised care planning, and multidisciplinary collaboration. Community-based support includes diabetes specialist nurses, virtual clinics, and education for patients with diabetes who are starting GLP-1 medications or insulin therapy.
In north central London, the National Diabetes Prevention Programme is delivered by Living Well Taking Control. The programme offers a structured nine-month behavioural intervention designed to support individuals with diabetes in adopting healthier eating habits, increasing physical activity, achieving weight reduction, and sustaining long-term lifestyle changes. Those needing insulin and other medicines to manage diabetes are also entitled to free prescriptions.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the provision of services for the treatment of type (a) 1 and (b) 2 diabetes in Hornsey and Friern Barnet constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
To improve the provision of services for the treatment of type 1 and 2 diabetes in the Hornsey and Friern Barnet constituency, the North Central London Integrated Care System has commissioned a long-term conditions service. This supports the identification of individuals with diabetes and at high risk of a worsening condition, personalised care planning, and multidisciplinary collaboration. Community-based support includes diabetes specialist nurses, virtual clinics, and education for patients with diabetes who are starting GLP-1 medications or insulin therapy.
In north central London, the National Diabetes Prevention Programme is delivered by Living Well Taking Control. The programme offers a structured nine-month behavioural intervention designed to support individuals with diabetes in adopting healthier eating habits, increasing physical activity, achieving weight reduction, and sustaining long-term lifestyle changes. Those needing insulin and other medicines to manage diabetes are also entitled to free prescriptions.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) improve care and treatment for people with eating disorders and (b) reduce the number of lives lost to eating disorders.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
As part of our mission to build a National Health Service fit for the future, there is a critical need to shift the treatment of eating disorders from hospital to the community. Improved care in the community will give young people early access to evidence-based treatment involving families and carers, improving outcomes and preventing relapse.
The Department is committed to learning from deaths in order to prevent future tragedies and improve the quality of care. The Department receives and responds to Prevention of Future Death reports relating to eating disorders and uses this work to inform practice. For example, the Medical Emergencies in Eating Disorders guidance was created following a coroner’s report and has since been rolled out nationwide.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve children's access to orthodontic treatment in Hornsey and Friern Barnet constituency.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
National Health Service orthodontic treatment is free for people under the age of 18 years old with a clear health need for treatment. Adult patients, and patients under the age of 18 years old who do not qualify for NHS orthodontic treatment, may choose to pay for private orthodontic treatment. Further information can be found at the following link:
The responsibility for commissioning primary care services, including NHS dentistry and orthodontic services, to meet the needs of the local population has been delegated to the integrated care boards (ICBs) across England. For the Hornsey and Friern Barnet constituency, this is the North Central London ICB.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Janssen on the adequacy of supply of the ADHD medication Concerta XL.
Answered by Andrew Stephenson
The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, including Concerta XL tablets, which are affecting the United Kingdom and other countries around the world. This has involved asking that suppliers expedite deliveries to boost supplies of these important medicines, and addressing regulatory issues to ensure continuity of supply. As a result of our ongoing activity and intensive work, some issues have been resolved. We expect the disruptions to the supply of Concerta XL tablets to be resolved in May 2024.
The Department held a roundtable with all suppliers of methylphenidate prolonged-release tablet suppliers, including Janssen, in April 2024, to discuss the challenges they are facing, what they are doing, and what needs to be done to address these issues.
We have worked closely with specialist clinicians during this time to develop management advice for the National Health Service. The guidance includes advice for ADHD service providers and specialists to offer rapid response to primary care teams seeking urgent advice for the management of patients. This includes those known to be at a higher risk of adverse impact because of these shortages.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure patients have access to Concerta XL.
Answered by Andrew Stephenson
The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, including Concerta XL tablets, which are affecting the United Kingdom and other countries around the world. This has involved asking that suppliers expedite deliveries to boost supplies of these important medicines, and addressing regulatory issues to ensure continuity of supply. As a result of our ongoing activity and intensive work, some issues have been resolved. We expect the disruptions to the supply of Concerta XL tablets to be resolved in May 2024.
The Department held a roundtable with all suppliers of methylphenidate prolonged-release tablet suppliers, including Janssen, in April 2024, to discuss the challenges they are facing, what they are doing, and what needs to be done to address these issues.
We have worked closely with specialist clinicians during this time to develop management advice for the National Health Service. The guidance includes advice for ADHD service providers and specialists to offer rapid response to primary care teams seeking urgent advice for the management of patients. This includes those known to be at a higher risk of adverse impact because of these shortages.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential implications for her policies of the report by Mahon, M.B. et al. entitled A meta-analysis on global change drivers and the risk of infectious disease, published in Nature on 8 May 2024.
Answered by Maria Caulfield
In December 2023 the UK Health Security Agency (UKHSA) published the Health Effects of Climate Change report, which is available at the following link:
https://www.gov.uk/government/publications/climate-change-health-effects-in-the-uk
This report details the potential risks and impacts of climate change on human health. The UKHSA will continue to work closely with other departments and agencies, to assess emerging evidence on drivers of infectious diseases, to inform future health policies.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with representatives of Unicef on (a) its Baby Friendly initiative and (b) trends in breastfeeding rates in the UK.
Answered by Andrea Leadsom
I met with representatives from UNICEF in March 2024 to discuss the Start for Life agenda. Through the Family Hubs and Start for Life Programme, we are investing £50 million into infant feeding services. This is enabling participating local authorities to design and deliver a blended offer to ensure all mothers can meet their breastfeeding goals. The investment is being used to increase the range of advice and support available, including peer support.
We are also investing to increase the capacity of the National Breastfeeding Helpline. In March 2024, we launched a trial of extended helpline opening hours, so that support and advice is available at any time of the day or night, every day of the year.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Novartis on the adequacy of supply of the epilepsy medication Tegretol.
Answered by Andrew Stephenson
The Department has been working intensively to address issues with the supply of some epilepsy medications, and as a result we have helped to resolve issues with Tegretol 200 milligram and 400 milligram prolonged release tablets, and Tegretol 100 milligram immediate release tablets. We are aware of a shortage of Tegretol 100 milligram/5 millilitre liquid, but have been advised that resupplies are expected this month. We are continuing to work closely with manufacturers, including Novartis, to help ensure the continued supply of these medicines for patients in the United Kingdom, for example by asking suppliers to expedite deliveries.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.
Asked by: Catherine West (Labour - Hornsey and Friern Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help tackle shortages of medicines in pharmacies.
Answered by Andrew Stephenson
The Department has a responsibility to work with United Kingdom medicine license holders, to help ensure continuity of supply. We monitor and manage medicine supply at a national level, so that stocks remain available to meet regional and local demand. There are approximately 14,000 medicines licensed for supply in the UK, and the overwhelming majority are in good supply. The medicine supply chain is complex, global, and highly regulated, and supply issues can be caused by a range of factors. For example, suppliers can encounter manufacturing problems, difficulty accessing raw materials, and surges in demand. These are commonly cited as the drivers of recent supply issues, which have affected many countries, not just the UK.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients at a national level. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.